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Abstract
Introduction: Kallmann syndrome (KS) is a rare congenital disorder combining hypogonadotropic hypogonadism (HH) due to GnRH- 
-deficiency with anosmia. Traditionally thought to require lifelong therapy, it has transpired to be a reversible condition in some patients. 
Material and methods: We present a case of a 22-year-old man with absent puberty due to KS, in whom genetic testing revealed heterozy-
gosity for a mutation in the PROK2 gene. Pubertal development and virilisation was achieved by using human chorionic gonadotropin 
(hCG) injections followed by testosterone replacement. During the follow-up, we observed reversal of hypogonadism allowing discon-
tinuation of testosterone treatment. Normalisation of testicular volume as well as gonadotropin and inhibin B levels through a two-year 
post-reversal period was seen.
Conclusions: Treatment with hCG is effective in inducing pubertal development and may have advantage over testosterone re-
placement due to potential gonadal maturation. Regular assessment of testicular volume and biochemical surveillance including 
measuring of serum inhibin B and gonadotropins are necessary for timely detection of reversal of GnRH deficiency. (Endokrynol 
Pol 2017; 68 (6): 692–696)
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Streszczenie
Wstęp: Zespół Kallmanna jest rzadkim, wrodzonym zaburzeniem łączącym hipogonadyzm hipogonadotropowy spowodowany niedobo-
rem GnRH z anosmią. Tradycyjnie uważany za wymagający leczenia przez całe życie u części pacjentów okazuje się stanem odwracalnym. 
Opis przypadku: Prezentujemy przypadek 22-letniego mężczyzny z brakiem cech pokwitania z powodu zespołu Kallmanna, u którego 
badanie genetyczne ujawniło heterozygotyczność dla mutacji genu PROK2. Rozwój cech pokwitania i wirylizacji osiągnięto, podając 
iniekcje ludzkiej gonadotropiny kosmówkowej (hCG), a stosując następnie leczenie testosteronem. Podczas obserwacji wystąpiło zjawi-
sko samoistnego ustąpienia hipogonadyzmu hipogonadotropowego (tzw. reversal), co pozwoliło na przerwanie leczenia testosteronem. 
W ciągu następnych 2 lat stwierdzono normalizację wielkości jąder, a także stężeń gonadotropin i inhibiny B. 
Wnioski: Leczenie hCG jest skuteczne w indukcji pokwitania i może mieć przewagę nad leczeniem testosteronem z uwagi na możliwość 
procesu dojrzewania jąder. Częsta ocena wielkości jąder i kontrola parametrów biochemicznych, takich jak stężenie gonadotropin i inhi-
biny B, są konieczne dla wczesnego wykrycia zjawiska reversal. (Endokrynol Pol 2017; 68 (6): 692–696)
Słowa kluczowe: zespół Kallmana, leczenie hCG, samoistne ustąpienie hipogonadyzmu hipogonadotropowego
Introduction
Kallmann syndrome (KS) is a rare congenital form of 
idiopathic hypogonadotropic hypogonadism (HH) 
in which gonadotropin-releasing hormone (GnRH) 
deficiency is associated with smell sense disorders due 
to hypoplasia or aplasia of the olfactory bulbs. KS is 
a clinically and genetically heterogeneous disease with 
a variable degree of hypogonadism and associated 
non-reproductive abnormalities as well as a complex 
genetic transmission. Typically, a lifelong therapy 
is required, but some patients exhibit spontaneous 
recovery of reproductive endocrine function, i.e. 
reversal [1, 2].
Case report
A 22-year-old man, with previous unremarkable medi-
cal history, was referred to our centre due to absence of 
puberty. Over the preceding few years, the patient had 
become aware of the inadequacy of his physical develop-
ment, concerning voice change, development of facial 
hair, and genital size. He self-reported anosmia. His older 
brother and younger sister underwent normal puberty. 
Malgorzata M. Pierzchlewska, M.D., Department of Endocrinology, Aalborg University Hospital. Medicinerhuset, Mølleparkvej 4,  
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At physical examination he had height of 1.82 m, 
weight of 80.3 kg, and no clear eunuchoidal propor-
tions. He had a light voice and no facial hair growth, 
but there were signs of normal adrenarche, i.e. sparse 
pubic and axillary hair growth. Pubic hair and phallic 
development were Tanner stage II. Both testes were 
prepubertal and found in the scrotum. Left and right 
testicular volume by ultrasound was 2.8 ml and 1.9 ml, 
respectively. No gynecomastia, hearing impairment, 
visual field defects or impaired visual acuity, bimanual 
synkinesia, midline defects, or skeletal abnormalities 
were observed. 
Bone age determined by radiographs was 17.5–18 
years. Bone densitometry (DEXA, Hologic) showed 
Z score of –1.8 and –0.2 at the lumbar spine and total 
hip, respectively. Abdominal ultrasound was normal. 
MRI showed pituitary gland of a normal size and ap-
pearance. Poorly developed olfactory sulci and absent/ 
/hypoplastic olfactory bulbs were noticed. 
Basal hormonal evaluation revealed very low tes-
tosterone level, low normal range LH and FSH levels, 
low inhibin B. Other hormonal measurements, includ-
ing hypophyseal hormones, were normal (Table I). 
A normal 46,XY karyotype was found.
Genetic testing was performed by PCR and next-
generation sequencing by Centogene AB, Rostock, 
Germany. The KS/HH NGS panel included 14 different 
genes (ANOS1, CHD7, FGF8, FGFR1, GNRH1, GRNHR, 
HESX1, KISS1, KISS1R, PROK2, PROKR2, SEMA3A, 
TAC3, TACR3). A single base pair deletion in exon 2 of 
the PROK2 gene (c.163delA p.155) was identified in the 
proband. Segregation analyses showed that the variant 
was inherited from the unaffected father. A detailed 
family anamnesis did not reveal other symptomatic 
family members.
Treatment with hCG (Pregnyl®) was started with 
a weekly dose of 1000 IU s.c., administered as 500 IU 
twice weekly, gradually increased up to 7000 IU per 
week, resulting in a gradual increase of testosterone 
level as well as pubertal development (Figure 1). After 40 
weeks of hCG treatment a satisfactory effect on virilisa-
tion and a 44% increase in combined testicular volume 
were achieved. Pubic hair and phallic development 
achieved Tanner stage IV. Left and right testicular vol-
ume by ultrasound was 3.6 ml and 4.8 ml, respectively. 
Sparse facial hair growth, facial acne, deepening of the 
voice and increased lean body mass became clearly 
manifest. Due to a prompt fall in testosterone level to 
the baseline value after cessation of hCG treatment, 
testosterone replacement therapy was initiated after a 
two-week treatment interruption, using long-acting tes-
tosterone undecanoate (Nebido®) at a dose of 1000 mg 
i.m. and injection interval of 15–16 weeks. During tes-
tosterone therapy an unexpected increase in inhibin B 
and gonadotropin levels was observed (Figure 2 and 3), 
which led to discontinuation of hormonal therapy 
after 14 months (five injections), considering a likely 
reversal of hypogonadism. Levels of testosterone and 
gonadotropins remained normal through a two-year 
Table I. Initial hormonal measurements
Tabela I. Pomiary poziomu hormonów
Hormone Value Reference
Total testosterone 0.65 nmol/L 10.3–27.4
Sex hormone binding globulin
(SHBG)
52 nmol/L 24–77
Androstenedione 2.72 nmol/L 1.7–6.9
Dehydroepiandrosterone sulphate 
(DHEA-S)
7920 nmol/L 3000–12000
17-hydroxy-progesterone 2.24 nmol/L < 8
Luteinising hormone (LH) 1.4 IU/L 1.7–8.6
Follicle-stimulating hormone (FSH) 2.0 IU/L 1.5–12.4
Inhibin B 52 pg/mL 55–300
Thyroid-stimulating hormone (TSH) 2.6 mIU/L 0.3–4.5
Total Triiodothyronine (T3) 1.9 nmol/L 1.1–2.5
Total Thyroxine (T4) 126 nmol/L 60–140
Cortisol 490 nmol/L 200–600
Adrenocorticotropic hormone 
(ACTH)
70 ng/mL 10–60
Insulin-like growth factor-1 
(IGF-1)
42 nmol/L 10–45
Insulin-like growth factor-binding 
protein 3 (IGF-BP3)
6030 ng/mL SDS 1.53
Prolactin 73.5 mIU/L 70–450
Figure 1. Testosterone levels and Tanner staging during hCG- 
-treatment
Rycina 1. Poziomy testosteronu i ocena w skali Tannera podczas 
leczenia hCG
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post-reversal period, and inhibin B continued to in-
crease (Figure 2 and 3). At the end of the follow-up, 
testicular volume was normal (left and right testicular 
volume by orchidometer: 17 and 20 ml, respectively), 
development of secondary sexual characteristics was 
completed, and psychosexual functioning as well as 
self-confidence improved. 
Discussion
Most patients with KS present as sporadic cases, but 
a proportion of cases are inherited. The commonest 
mode of inheritance is X-linked recessive, as seen in 
affected males with mutations in KAL1 (ANOS1), the 
first described gene for KS. During the last two decades, 
however, a substantial number of other genes have been 
found to cause normosmic HH (nHH) and KS also in 
autosomal dominant and autosomal recessive inherit-
ance patterns, and so the complexity of genetic testing 
and its prioritising has become a challenge for clini-
cians. Costa-Barbosa et al. [3] have proven that certain 
clinical features of KS, such as unilateral renal agenesis, 
bimanual synkinesia, dental agenesis, and syndactyly, 
are highly associated with mutations in specific genes. 
Our patient did not exhibit any of the anomalies that 
could help with prioritising genetic screening. The 
pedigree suggested an autosomal recessive mode of 
inheritance in this family or a de novo mutation in the 
patient. The only genetic defect we found in this patient 
was a monoallelic mutation (c.163delA p.155) in the 
PROK2 gene, coding for prokineticin 2 peptide. The 
prokineticin 2 signalling pathway plays a critical role 
in olfactory bulb development and reproductive matu-
ration in mammals. Loss-of-function mutations in the 
PROK2 and PROKR2 genes, the latter coding for proki-
neticin receptor, are a newly discovered molecular basis 
of autosomal KS [4]. Non-reproductive, non-olfactory 
anomalies, such as fibrous dysplasia, sleep disorders, 
synkinesia, and epilepsy [5], are rare and occur mostly 
in male patients with monoallelic mutations, whereas 
those with biallelic mutations have severe reproductive 
changes, such as micropenis and cryptodorchism [6]. 
Those mutations are predominantly detected in the 
heterozygous state with incomplete penetrance and 
variable expressivity. Homozygous and compound 
heterozygous changes are rare, but they have already 
been described, for this particular PROK2 mutation by 
Pitteloud et al. [7]. The authors described KS or nHH 
in three siblings who harboured the homozygous 
deletion. Contrary to our case, normal puberty and 
fertility was observed in the other two siblings, who 
were heterozygous for the mutation. However, the 
spectrum of clinical manifestations in family members 
with the same monoallelic mutation in the PROK2 and 
PROKR2 genes can range greatly from no symptoms, 
through partial or absent puberty but normal olfaction, 
anosmia/hyposmia but normal pubertal development, 
to full-blown KS. Due to this phenotypic heterogene-
ity, it has been postulated that the heterozygous state 
for a PROK2/PROKR2 mutation alone is not sufficient 
to cause KS or nHH phenotype, and that monoallelic 
cases are in fact digenic or oligogenic, in that they also 
carry additional mutations in other genes known (or 
currently unknown) to cause GnRH deficiency [8]. Not 
dismissing this possibility, we suggest that the family 
might demonstrate incomplete penetrance of the muta-
tion, and factors we do not yet understand permit both 
the asymptomatic presentation of the father and the 
full KS spectrum of the son carrying the same monoal-
lelic mutation. The reduced penetrance of the disease 
could also facilitate the reversal of hypogonadism in 
this patient. 
Figure 3. Inhibin B during hCG-treatment, testosterone therapy, 
and after cessation of treatment
Rycina 3. Poziomy inhibiny B podczas leczenia hCG, testosteronem 
i po zaprzestaniu leczenia
Figure 2. Testosterone, FSH, and LH levels during testosterone 
therapy and after cessation of treatment
Rycina 2. Poziomy testosteronu, FSH i LH podczas leczenia 
testosteronem i po jego zaprzestaniu
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The standard management of male adolescents and 
young adults with HH is to use testosterone replacement 
to induce virilisation and psycho-sexual maturation 
[9]. However, testosterone treatment in those patients 
will not induce testicular growth or spermatogenesis. 
Furthermore, Liu et al. [10] have shown that prior tes-
tosterone therapy is associated with a slower response 
to subsequent fertility treatment with gonadotropins, 
suggesting that the use of testosterone for pubertal 
induction may have an adverse effect on fertility po-
tential by preventing maturation of testes. The use of 
gonadotropins as a physiologic stimulus of testes seems 
to provide some benefit in enhancing testicular growth 
and inducing spermatogenesis [11]. Therapy with hCG 
alone, the hormone with a predominant LH-activity, has 
a marked effect on testosterone levels, regardless of the 
initial testicular volume, while the effect on testicular 
growth and sperm production is related to the initial 
volume of testes [11]. Interestingly, a recent multicentre 
prospective study [12] has delivered further arguments 
for early gonadotropin treatment in adolescents with 
HH. The authors have shown that the combined treat-
ment with hCG and recombinant follicle-stimulating 
hormone (rFSH) is a safe means of inducing all features of 
pubertal development, including the acquisition of fertil-
ity and a marked improvement of quality of life, regard-
less of previous testosterone replacement. The plasma 
half-life of hCG is long enough to allow administration 
twice a week in the form of subcutaneous injections. It 
can be self-administered by the patient after a proper 
instruction. Our patient tolerated the treatment well. 
We aimed at achieving testosterone levels at the lower 
end of normal range to induce a more rapid virilisation. 
Since the primary objective of treatment was to induce 
virilisation and not fertility, the possibility of adding 
rFSH to hCG treatment [12, 13] was not considered at 
this stage. The decision to switch over to testosterone 
replacement in our patient after a 10-month period of 
hCG treatment was arbitrary due to lack of evidence to 
suggest the optimal duration of gonadotropin exposure 
in this clinical context. 
An interesting feature of KS is a spontaneous activa-
tion of the hypothalamic-pituitary-gonadal (HPG) axis, 
termed reversal, occurring mostly in male patients dur-
ing early adulthood [1]. Sidhoum et al. [2], assessing of 
a large cohort of 308 patients, found a lifetime incidence 
of reversal of GnRH deficiency to be 15–22%. Reversal 
can occur even in patients with cryptodorchism and 
micropenis, and no preponderance of a specific genetic 
spectrum that favours reversal is seen. Furthermore, in 
a small subset of patients the reversal is not permanent 
and relapse can occur. Increasing testicular volume 
under testosterone treatment and a rise in testoster-
one levels after cessation of testosterone replacement 
are the typical features of reversal. In our patient, we 
observed two distinct biochemical changes that raised 
this suspicion. Firstly, we found an unexpected increase 
in gonadotropin levels at the time of the third testos-
terone injection. Secondly, levels of inhibin B, initially 
suppressed after commencing hCG treatment, began 
to rise in the last 16 weeks of the hCG period and rose 
continuously under testosterone treatment, despite ces-
sation of hCG exposure. We suggest that rising levels of 
gonadotropins and inhibin B may be the early biochemi-
cal features of reversal during ongoing testosterone 
replacement. In the presented case, reversal must have 
occurred at any time between the first and the third 
testosterone injection, i.e. over a time span of 30 weeks, 
suggesting that a closer biochemical surveillance would 
be more appropriate for early detection of reversal and 
thus timely discontinuation of testosterone. 
Conclusions
The use of hCG to induce puberty in young male adults 
with KS is clinically effective, allows precise titration to 
achieve adequate testosterone levels, and may have an 
advantage over testosterone replacement due to poten-
tial gonadal maturation. Regular assessment of testicular 
volume and biochemical surveillance including are cru-
cial for timely detection of reversal of GnRH deficiency. 
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